New Dutch Government Must Ensure Transparency to Control Medicine Prices

by JAUME VIDAL After almost seven months of negotiations, The Netherlands has formed a new coalition government, which recently outlined its priorities and main policy objectives in its Coalition Agreement. On the whole, it’s good news from an access to medicines perspective—particularly pricing and procurement, which remain high on the government’s priority list. Some of [...]

Staff Spotlight: Tim Reed

A famous man, John Quincy Adams, once said, “If your actions inspire others to dream more, learn more, do more and become more, you are a leader”. Mr Adams was the sixth president of the United States of America—and the first to give an interview to a female journalist, Anne Royall, which was quite progressive for his time.

Giving Snakebite Victims a Voice

Health Action International Presents “Minutes to Die” at the Dutch Global Health Film Festival

by BIRTE BOGATZ, Communications Advisor

How do you measure the burden of a health emergency? We often tend to do that by counting—the dead, the disabled, the dollars to be paid for treatment. We end up with numbers,

Staff Spotlight: Gemma Buckland-Merrett

We open the curtain on part three of our “Staff Spotlight” blog series, taking you backstage at Health Action International.
Behind every report, every consultation response, policy brief or methodology there’s a person—most of the time even more than one, because Policy Advisors, Project Managers, Communications & Co. here at HAI work hand in hand.

Insulin Still Unattainable for Many Living with Diabetes Worldwide: ACCISS Study Review in The Lancet D&E


An ACCISS Study Review of the global insulin market, called ‘Constraints and Challenges in Access to Insulin: A Global Perspective, was published Friday in The Lancet Diabetes & Endocrinology. Co-authored by ACCISS Study leaders, David Beran, Marg Ewen and Richard Laing, the Review describes why insulin is still unattainable for approximately half of all people who need it.

The EU-US Trade Deal Could Leave Europeans Sick

Some help us for a while. Some cure us entirely. No doubt, medicines—when they’re available and affordable—play a crucial role in helping us live better quality and longer lives than ever before. So, why, then, would the European Commission do anything that would risk citizens’ ability to access the medicines we need?

HAI Launches Innovative Global Study to Improve Access to Insulin

by MARG EWEN, Global Pricing Co-ordinator and ACCISS Study Co-investigator

The global need for insulin, a hormone that converts sugar, starches and other food into needed energy for everyday activities, is immense. An estimated 100 million people with diabetes need it. This includes all with type 1 diabetes, plus 20 to 30 per cent of people with type 2 diabetes.

New materials help assess medicines policies and interventions


Many countries, no matter their geographic region or level of economic development, have tremendous opportunity to improve medicines prices, availability and affordability for their citizens. To aid in this endeavour, various medicines policies and interventions exist. It can be difficult, however, for countries to determine which policies and interventions to implement;

DG Trade State of Play reveals EU's ambitions for IP protection in FTAs

The EU will not be changing its aggressive approach to IP protection in bilateral trade agreements, according to the updates that representatives from the European Commission gave at a State of Play meeting with civil society on June 27, 2011. Despite years of opposition and outrage by the global public health community, the EU continues to pursue high IP standards in trade deals with developing countries.

Report exposes how Big Pharma has hijacked EU-India trade deal

The livelihoods of millions of patients are at risk under the terms of a new trade deal being negotiated by the EU and India which has been hijacked by big business, highlights a new joint report from Corporate Europe Observatory and India FDI.

Trade Invaders – How big business is driving the EU-India free trade negotiations